Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00061425
Status:
COMPLETED
Last Update Posted:
2021-08-19
First Post:
2003-05-27
Brief Title:
Treatment of Non-Hodgkins Lymphoma With 90Y-hLL2 IgG
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
Phase III Radioimmunotherapy of Non-Hodgkins Lymphoma With Radiolabeled Humanized Immuno-LL2 Treatment With 90Y-hLL2 IgG
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to determine the safety of a 90Y-radiolabeled humanized CDR-grafted form of the LL2 monoclonal antibody in patients with Non-Hodgkins lymphoma NHL at different dose levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None